{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2023)
Source URL:
First approved in 1968
Source:
NDA204426
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
INN:pegmolesatide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ormutivimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:rimteravimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tamrintamab pamozirine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03704766: Not Applicable Interventional Recruiting Joint Infection
(2016)
Source URL:
Class:
PROTEIN
